Mubasher: The UK’s pharmaceutical giant AstraZeneca announced that its coronavirus (COVID-19) vaccine, developed in collaboration with the University of Oxford, could be about 90% effective.
Late-stage trials, conducted in the UK and Brazil, showed that the vaccine can be 90% effective when it was administered as a half dose, followed by a full dose at least a month apart, according to a statement on Monday.
The other dosing regimen showed 62% efficacy when administered as two full doses at least one month apart.
“No hospitalisations or severe cases of the disease were reported in participants receiving the vaccine,” the company said.
“The vaccine can be stored, transported, and handled at normal refrigerated conditions (2-8 degrees Celsius/ 36-46 degrees Fahrenheit) for at least six months and administered within existing healthcare settings.”
The company plans to produce up to 3 billion of doses in 2021 after obtaining regulatory approval.
AstraZeneca will distribute the vaccine at no profit during the pandemic.
Earlier, Pfizer's vaccine reported preliminary results showing an efficacy of 95% against COVID-19, while Moderna's vaccine was 94.5% effective in preventing COVID-19 based on interim data from a late-stage trial.